News
Zacks.com on MSN4d
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback